Lilly warns some GLP-1 Medicare patients could exceed $50 monthly costs
Lilly warned that under the CMS BALANCE model a segment of Medicare Part D patients could pay above $50 monthly for its obesity GLP-1 drugs. BALANCE begins for Medicaid in May 2026 and Medicare Part D in January 2027, and Lilly is launching education on coverage alternatives and assistance.
1. BALANCE Model Timeline
The BALANCE program will roll out for Medicaid in May 2026 and for Medicare Part D in January 2027, enabling CMS to negotiate GLP-1 drug rates and target a $50 monthly cost for most enrollees.
2. Cost-Sharing Exceptions
Lilly cautioned that certain basic Medicare Part D plans could impose cost sharing above $50 per month for its obesity and weight-loss therapies, exposing a small subset of patients to higher out-of-pocket expenses.
3. Lilly’s Patient Support Initiatives
In response, Lilly is launching educational efforts for patients and healthcare providers to highlight alternative coverage pathways and financial assistance programs aimed at reducing individual cost burdens.